The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Biomarker validation for treatment sequencing in pancreatic NETs
Ramon Salazar, MD, PhD, Institut Català D’Oncologia, Barcelona, Spain, discusses the SEQTOR trial (NCT02246127), which examined sequencing therapies in advanced pancreatic neuroendocrine tumors (panNETs). While promising, the biomarker findings require further validation in ongoing Phase III trials. The potential for a more personalized approach to panNETs treatment hinges on validating these biomarkers, emphasizing the need for continued research in this field to optimize patient outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
